Finally, we took advantage of previously developed gene expression “read outs” resulting from experimentally controlled oncogenic pathway activation (src, b-catenin and E2F3) to assess activation status in individual tumor samples [12], [27]. The gene discussed is E2F3; the disease is neoplasm.